SI1061940T1 - Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders - Google Patents

Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders

Info

Publication number
SI1061940T1
SI1061940T1 SI9930515T SI9930515T SI1061940T1 SI 1061940 T1 SI1061940 T1 SI 1061940T1 SI 9930515 T SI9930515 T SI 9930515T SI 9930515 T SI9930515 T SI 9930515T SI 1061940 T1 SI1061940 T1 SI 1061940T1
Authority
SI
Slovenia
Prior art keywords
follistatin
medicament
muscle
manufacture
treatment
Prior art date
Application number
SI9930515T
Other languages
Slovenian (sl)
Inventor
Clive R. Wood
Lori Jo Fitz
Original Assignee
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/037,118 external-priority patent/US6004937A/en
Application filed by Genetics Institute, Llc filed Critical Genetics Institute, Llc
Publication of SI1061940T1 publication Critical patent/SI1061940T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SI9930515T 1998-03-09 1999-02-24 Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders SI1061940T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/037,118 US6004937A (en) 1998-03-09 1998-03-09 Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
EP99908416A EP1061940B1 (en) 1998-03-09 1999-02-24 Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders
PCT/US1999/004003 WO1999045949A2 (en) 1998-03-09 1999-02-24 Use of follistatin to modulate gdf-8 and bmp-11

Publications (1)

Publication Number Publication Date
SI1061940T1 true SI1061940T1 (en) 2004-04-30

Family

ID=32178771

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930515T SI1061940T1 (en) 1998-03-09 1999-02-24 Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders

Country Status (1)

Country Link
SI (1) SI1061940T1 (en)

Similar Documents

Publication Publication Date Title
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0003381A3 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
EP1063990A4 (en) Therapy of estrogen-associated disorders
HUP0104709A3 (en) Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
EP1191941A4 (en) A method for the prophylaxis and/or treatment of medical disorders
HK1053058A1 (en) Use of pramipexole for the treatment of addictive disorders
AU6910600A (en) Methods for the treatment of mental disorders
EP1126850A4 (en) Treatment of disorders of the outer retina
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
GB9926968D0 (en) Treatment of neurological disorders
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
AU7106300A (en) Treatment of skin disorders
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
IL131347A0 (en) Treatment of skin disorders
SI1061940T1 (en) Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis
GC0000176A (en) Pharmaceutical combination preparations for the treatment of cardiac disorders
GB2332626B (en) Medicaments for treatment of disorders of the middle ear